1.. INTRODUCTION
================

In the gastrointestinal (GI) tract, 5-hydroxytryptamine (serotonin, 5-HT) is a major signaling molecule, which mediates GI functions (motility and secretion), emesis, nausea and pain \[[@R1],[@R2]\]. Most of colonic 5-HT is synthesized and released from mucosal enterochromaffin (EC) cells; therefore, alterations in the release of 5-HT from EC cells affect both physiological and pathophysiological colonic functions \[[@R2]\].

Irritable bowel syndrome (IBS) is a GI chronic disorder characterized by abdominal discomfort or pain associated with altered bowel habits. Abnormal levels of chromogranin A (a marker for all endocrine cells) in the colon of IBS patients have been demonstrated \[[@R3]\], thus indicating a role of the colonic endocrine cells (namely, 5-HT-containg EC cells or peptide YY (PYY)-containing L cells), in the regulation of colonic function in IBS patients \[[@R4]-[@R6]\]. Indeed, a recent human study \[[@R7]\] suggests that the increased 5-HT release from colonic EC cells contributes to the development of abdominal pain in IBS patients. Therefore, an improved understanding of endogenous modulator system for 5-HT release from EC cells may provide novel insights into the etiology and pharmacotherapy of functional bowel disorders such as IBS.

Our *in vitro* studies have demonstrated that isolated guinea-pig colon is a helpful *in vitro*-preparation for studying the mechanism modulating the release of 5-HT from EC cells \[[@R8]-[@R10]\]. Experimental data from the *in vitro*-preparations indicate that melatonin, endogenous tachykinins (TKs; neuropeptides such as substance P and neurokinin A) and PYY play important roles in the modulation of the release of 5-HT from EC cells *via*a unique endogenous tachykinergic NK~2~/NK~3~ receptor cascade system \[[@R8]-[@R11]\]. This review focuses on the evidence establishing a potential role of the endogenous NK~2~/NK~3~ receptors cascade system controlling the release of 5-HT from EC cells, with special attention being paid to the pathophysiology of gut disorders including IBS.

2.. TACHYKININ RECEPTORS AND 5-HT RELEASE FROM COLONIC MUCOSA
=============================================================

A selective tachykinin NK~2~receptor agonist βAla-NKA-(4-10) (0.01-1 μM) evoked a long-lasting 5-HT release from isolated guinea-pig colon in a concentration-dependent manner \[[@R8]-[@R11]\]. The 5-HT-releasing action of βAla-NKA-(4-10) was unaffected by tetrodotoxin (TTX), and was also seen in myenteric plexus-free mucosal preparations, thus suggesting that the NK~2~ agonist-evoked 5-HT release is mediated by activation of NK~2~ receptors located on non-neuronal cells in the mucosal layer \[[@R8]\]. This agrees with a previous report which showed tachykinin NK~2~ receptor expression on the surfaces of enterocytes of guinea-pig colon \[[@R12]\]. The L-type calcium channel blocker nicardipine or the syntaxin inhibitor botulinum toxin type C also reduced the long-lasting 5-HT release evoked by βAla-NKA-(4-10) \[[@R9]\], thus suggesting that the NK~2~ receptor-triggered 5-HT release is mediated *via*syntaxin-related exocytosis mechanisms. However, an involvement of tachykinin NK~1~ receptors in the evoked 5-HT release is unlikely because a selective tachykinin NK~1~ receptor agonist, \[Sar^9^, met (O~2~)^11^\]-substance P (100 nM) failed to affect basal 5-HT release \[[@R9]\].

A selective tachykinin NK~3~ receptor agonist senktide also evoked a transient 5-HT release from the isolated guinea-pig colon implicating tachykinin NK~3~ receptors, in addition to NK~2~ receptors in modulating 5-HT release from colonic mucosa \[[@R8]\]. As summarized in Fig. **[1](#F1){ref-type="fig"}**, the enhancing effect of senktide on 5-HT release was prevented by both TTX and the NK~2~ receptor-selective antagonist SR48968, thus suggesting that senktide stimulates the release of neuronal TKs, which in turn enhances 5-HT release *via*mucosal NK~2~ receptors. This agrees with previous findings in guinea-pig colon where NK~3~ receptor activation releases TKs and 5-HT \[[@R13],[@R14]\]. The 5-HT-releasing action of senktide was also inhibited by hexamethonium, and was not seen in myenteric plexus-free mucosal preparations, thus suggesting that myenteric cholinergic interneurons also participate in the mechanism for NK~3~ receptor-triggered 5-HT release \[[@R8]\]. Thus, these findings support the view that the cascade of neuronal NK~3~ receptors and mucosal NK~2~ receptors represents an endogenous modulator system for 5-HT release from EC cells.

These results are also in line with previous findings (1) in human colon where NK~3~ receptors present predominantly on myenteric and submucosal plexus neurons, and NK~3~ receptors come into a play only in pathological conditions such as rescue responses or inflammation \[[@R15]\], and (2) in healthy volunteers where the stimulation of NK~2~ receptors appears to induce IBS-like symptoms \[[@R16]\]. Moreover, it has been shown that the 5-HT release from mucosal biopsy specimens of IBS patients is increased by 10-fold over controls, and the increased 5-HT release contributes to development of abdominal pain in IBS patients \[[@R7]\]. Therefore, the view that the endogenous tachykininergic NK~2~/NK~3~ receptor cascade system can regulate the release of 5-HT from colonic EC cells, has an important implication for the potential role of endogenous TKs in the generation of the symptoms associated with IBS; it can be speculated that endogenous TKs acting through the NK~2~/NK~3~ receptor cascade system facilitate the release of 5-HT which in turn affects the colonic function of IBS patients through the activation of 5-HT receptor subtypes.

A sensory nerve-derived neuropeptide, calcitonin gene-related peptide (CGRP, 1-100 nM) has been also shown to produce a TTX-sensitive but atropine-resistant 5-HT release *via*stimulation of myenteric plexus neurons in the isolated segments of guinea-pig colon \[[@R8]\]. The enhancing effect of CGRP on 5-HT release was also prevented by both the NK~2~ receptor-selective antagonist SR48968 and the NK~3~ receptor-selective antagonist SR142801, but not by the NK~1~ receptor-selective antagonist L703606 \[[@R8]\]. Thus, these findings support the view that CGRP stimulates the release of neuronal TKs, which in turn enhances 5-HT release *via*the endogenous NK~2~/NK~3~ receptor cascade system. Thus, it appears that CGRP-sensitive TKs-releasing neurons play a role in activating the endogenous NK~2~/NK~3~ receptor cascade system. This conjecture is also supported by a previous report which showed that CGRP can stimulate intramural tachykinergic neurons in the guinea-pig colon \[[@R17]\]. Furthermore, the evidence for the elevation of the levels of endogenous CGRP and TKs in human diseased colonic mucosa has also been demonstrated \[[@R18],[@R19]\]; irritants, immunological and inflammatory mediators can release TKs and CGRP within the intestinal wall where these peptides may facilitate the release of 5-HT *via*the endogenous NK~2~/NK~3~ receptor cascade system. Thus, these findings suggest a possible role of the endogenous NK~2~/NK~3~ receptor cascade system controlling the release of 5-HT from EC cells in pathophysiological conditions that are associated with an upregulation of CGRP or TKs release.

3.. NK~2~ RECEPTOR-TRIGGERED 5-HT RELEASE IS MEDIATED BY ENDOGENOUS PYY
=======================================================================

The 36 amino-acid long peptide, peptide YY (PYY) is known as a major peptide hormone, which regulates colonic functions (motility and secretion) and appetite by acting *via*different neuropeptide Y receptor subtypes \[[@R20],[@R21]\]. In the colon, PYY is mainly synthesized and released into the blood from mucosal L cells. The blood PYY levels have been shown to increase rapidly in response to food ingestion, and the postprandial blood PYY levels remain elevated for several hours \[[@R21]\]. Abnormal levels of PYY in large intestinal endocrine cells have also been reported in patients with IBS \[[@R6],[@R22]\], indicating a possible role of PYY in the generation of the symptoms associated with IBS.

The NK~2~ receptor agonist, βAla-NKA-(4-10) (10-100 nM) also evoked a long-lasting and TTX-resistant PYY release from isolated guinea-pig colonic mucosa \[[@R11]\], thus suggesting that activation of NK~2~ receptors on the mucosal layer induces a long-lasting PYY release from L cells. As shown in Fig. **[2](#F2){ref-type="fig"}**, pretreatment with the neuropeptide Y~1~ receptor-selective antagonist BIBO3304 attenuated the βAla-NKA-(4-10)-evoked 5-HT release \[[@R11]\]. These findings support the hypothesis that activation of NK~2~ receptors on PYY-containing L cells provokes the release of PYY, which in turn activates mainly Y~1~ receptors located on EC cells to induce 5-HT release (Fig. **[3](#F3){ref-type="fig"}**). This hypothesis is further corroborated by findings that exogenously applied PYY (10 nM) evoked a long-lasting and BIBO3304-sensitive 5-HT release with a time course similar to that found for the NK~2~ agonist-evoked 5-HT release \[[@R11]\]. Overall, the above observations indicate that endogenously released PYY play a fundamental role in the NK~2~ receptor-triggered 5-HT release from EC cells; PYY-containing L cells appears to control 5-HT release from EC cells (Fig. **[3](#F3){ref-type="fig"}**). Given that food intake is a major and physiologically significant factor stimulating the release of PYY from mucosal L cells \[[@R21]\] and both PYY and 5-HT are well-known mediators of nausea and vomiting \[[@R23]\], it is hypothesized that the cascade of NK~2~ receptors on PYY-containing L cells and Y~1~ receptors on EC cells (Fig. **[3](#F3){ref-type="fig"}**) might play a role in the generation of postprandial symptoms (nausea and vomiting) in patients with IBS; in fact, a postprandial increase in plasma 5-HT levels have been shown to be related to the generation of postprandial symptoms in diarrhea-predominant IBS \[[@R24],[@R25]\]. Therefore, the NK~2~ receptor-triggered PYY release from colonic mucosa may be expected as a pharmacological target for postprandial symptoms in functional bowel disorders including IBS. Activation of tachykinin NK~3~ receptors on enteric cholinergic neurons has also been shown to provoke the release of PYY from colonic mucosa \[[@R26]\]. Thus, to elucidate whether the endogenous tachykinergic NK~2~/NK~3~ receptor cascade system participates in the mechanism for food intake-induced PYY release, is an interesting topic for future study.

4.. INHIBITION OF NK~2~ RECEPTOR-TRIGGERED 5-HT RELEASE BY MELATONIN
====================================================================

The 5-HT-derived neurohormone, melatonin (MT) is mainly synthesized in the pineal gland as well as in 5-HT-rich EC cells of the intestinal mucosa \[[@R27]\]. It has been shown that exogenous MT modulates colonic motility and pain in IBS patients \[[@R28],[@R29]\]; therefore, MT is considered as a possible therapeutic agent for IBS \[[@R29],[@R30]\]. In the isolated guinea-pig colonic mucosa, MT has been shown to inhibit the NK~2~ receptor-triggered 5-HT release by acting through MT~3~ melatonin receptors located on the mucosal layer, thus suggesting a possible role of MT as a negative-regulator for the NK~2~ receptor-triggered 5-HT release from EC cells \[[@R10]\] (Fig. **[2](#F2){ref-type="fig"}**). It is not yet known whether or not endogenous MT participates in the pathogenesis of IBS, but oral MT has been shown to reduce abdominal pain and the sensation of bowel urgency in IBS patients \[[@R29]\]. It is therefore to be expected that if low MT concentrations in the colonic mucosa facilitate 5-HT release from EC cells, the enhanced 5-HT release leads to abdominal pain in IBS patients. In fact, it has been shown that IBS patients have lower MT levels compared with healthy controls \[[@R31]\]. Thus, to elucidate whether the endogenous NK~2~/NK~3~ receptor cascade system participates in the modulatory effect of MT on colonic motility or pain, is an interesting topic for future study.

5.. CONCLUDING REMARKS
======================

The present review shows that the cascade pathway of NK~3~ receptors on cholinergic interneurons and NK~2~ receptors on PYY-containing endocrine L cells represents an endogenous modulator system for 5-HT release from colonic EC cells, and that melatonin, endogenous TKs and PYY play important roles in the modulation of the release of 5-HT from EC cells *via*the endogenous NK~2~/NK~3~ receptor cascade system (Fig. **[3](#F3){ref-type="fig"}**). Given that TKs, 5-HT-containing EC cells, PYY-containing L cells and melatonin play important roles in the pathophysiological regulation of colonic functions in the diseased gut including IBS, the potential role of the endogenous NK~2~/NK~3~ receptor cascade system controlling the release of 5-HT from EC cells, will undoubtedly be a focus of future investigations.
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![Effects of tetrodotoxin (+TTX, 1 μM), SR48968 (+SR, 1 μM) and hexamethonium (+C6, 100 μM) on the 5-HT release from isolated guinea-pig colon by senktide (100 nM). Senktide had no effect on the 5-HT release from myenteric plexus-free mucosal preparations (MP-free). Height of columns: 5-HT release expressed as % of the control. \* P \< 0.01, significantly different from the None (no antagonists); \*\* P \< 0.01, significantly different from the control.](CN-13-830_F1){#F1}

![Effect of βAla-NKA-(4-10) (100 nM, from 120 to 140 min of incubation), in the absence and presence of BIBO3304 (+BIBO, 100 nM, from the onset of incubation) or melatonin (+MT, 1μM, from 120 to 160 min of incubation) on the 5-HT release from isolated guinea-pig colonic mucosa. Ordinates: 5-HT release expressed as % of the control. Abscissae: time after onset of collection of the incubation medium. \* P \< 0.05, significantly different from the βAla-NKA.](CN-13-830_F2){#F2}

![An illustration of the working model of the endogenous tachykinergic NK2/NK3 receptor cascade system controlling the release of 5-HT/PYY from colonic mucosa: Interactions between enteric neurons (cholinergic interneuron and postganglionic tachykinergic neuron) and endocrine cells (PYY-containing L cell and 5-HT-containning EC cell) are present, where their activation potentially induces a long-lasting 5-HT/PYY release from colonic mucosa. We propose that NK3 receptor on cholinergic interneuron is located upstream of nicotinic receptor (N) on postganglionic tachykinergic neuron, and activation of NK2 receptor on L cell can provoke a long-lasting release of PYY, which in turn activate Y1 receptor on EC cell to induce a long-lasting 5-HT release (Melatonin inhibits the 5-HT release). The evoked long-lasting 5-HT release could participate in the generation of abdominal pain or nausea and vomiting in functional bowel disorders including IBS. CGRP-sensitive TKs-releasing neurons appear to play a role in activating the endogenous tachykinergic NK2/NK3 receptor cascade system.](CN-13-830_F3){#F3}
